An open-label, randomized, two-treatment, two period crossover, single-dose study to determine the relative bioavailability of fixed combination of final market image aliskiren/valsartan 75/160 mg tablets and the free combination of aliskiren 75 mg and valsartan 160 mg in healthy subjects

Trial Profile

An open-label, randomized, two-treatment, two period crossover, single-dose study to determine the relative bioavailability of fixed combination of final market image aliskiren/valsartan 75/160 mg tablets and the free combination of aliskiren 75 mg and valsartan 160 mg in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2007

At a glance

  • Drugs Aliskiren; Valsartan
  • Indications Diabetes mellitus; Heart failure; Hypertension; Myocardial ischaemia
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 21 Jun 2007 Status change from in progress to completed
    • 01 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top